Apolizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Apolizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target HLA-DR beta
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒N☑Y (what is this?)  (verify)

Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers.[1][2] Development was abandoned in 2005 because of toxic effects and lack of efficacy in human patients. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia[3]. There are no current clinical trials into its use.[4]

References[edit]

  1. ^ Bayes M; Rabasseda X; Prous J (2003). "Gateways to clinical trials". Methods Find Exp Clin Pharmacol. 25 (9): 747–71. PMID 14685303.
  2. ^ Rech, J; Repp, R; Rech, D; Stockmeyer, B; Dechant, M; Niedobitek, G; Gramatzki, M; Valerius, T (2006). "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study". Leukemia & Lymphoma. 47 (10): 2147–54. doi:10.1080/10428190600757944. PMID 17071489.
  3. ^ Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC (December 2009). "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia". Leuk. Lymphoma. 50 (12): 1958–63. doi:10.3109/10428190903186486. PMID 19860603.
  4. ^ http://adisinsight.springer.com/drugs/800006415